Cargando…

Excipient lung disease in a patient taking the benzodiazepine derivative etizolam: A case report

Excipient Lung Disease is an inflammatory response to the intravenous administration of oral formulations of drugs and their excipients (additives). Previously described offenders include opioids and Ritalin, whose excipients, when crushed and administered intravenously, lead to inflammation and are...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Ben C, Grant, Thomas, Allen, Bradley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818925/
https://www.ncbi.nlm.nih.gov/pubmed/35145565
http://dx.doi.org/10.1016/j.radcr.2022.01.035
_version_ 1784645940155514880
author Smith, Ben C
Grant, Thomas
Allen, Bradley
author_facet Smith, Ben C
Grant, Thomas
Allen, Bradley
author_sort Smith, Ben C
collection PubMed
description Excipient Lung Disease is an inflammatory response to the intravenous administration of oral formulations of drugs and their excipients (additives). Previously described offenders include opioids and Ritalin, whose excipients, when crushed and administered intravenously, lead to inflammation and are demonstrated by centrilobular nodules and ground-glass formations on Chest Computed Tomography. In this case report, we demonstrate Chest CT findings of excipient lung disease in a patient using etizolam, a benzodiazepine derivative commonly used as an anxiolytic in Japan. Of note, the patient acquired etizolam for purchase through online retailers without prescription, which is becoming more common occurrence and offers the additional risk of unknown formulations.
format Online
Article
Text
id pubmed-8818925
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88189252022-02-09 Excipient lung disease in a patient taking the benzodiazepine derivative etizolam: A case report Smith, Ben C Grant, Thomas Allen, Bradley Radiol Case Rep Case Report Excipient Lung Disease is an inflammatory response to the intravenous administration of oral formulations of drugs and their excipients (additives). Previously described offenders include opioids and Ritalin, whose excipients, when crushed and administered intravenously, lead to inflammation and are demonstrated by centrilobular nodules and ground-glass formations on Chest Computed Tomography. In this case report, we demonstrate Chest CT findings of excipient lung disease in a patient using etizolam, a benzodiazepine derivative commonly used as an anxiolytic in Japan. Of note, the patient acquired etizolam for purchase through online retailers without prescription, which is becoming more common occurrence and offers the additional risk of unknown formulations. Elsevier 2022-02-03 /pmc/articles/PMC8818925/ /pubmed/35145565 http://dx.doi.org/10.1016/j.radcr.2022.01.035 Text en © 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Smith, Ben C
Grant, Thomas
Allen, Bradley
Excipient lung disease in a patient taking the benzodiazepine derivative etizolam: A case report
title Excipient lung disease in a patient taking the benzodiazepine derivative etizolam: A case report
title_full Excipient lung disease in a patient taking the benzodiazepine derivative etizolam: A case report
title_fullStr Excipient lung disease in a patient taking the benzodiazepine derivative etizolam: A case report
title_full_unstemmed Excipient lung disease in a patient taking the benzodiazepine derivative etizolam: A case report
title_short Excipient lung disease in a patient taking the benzodiazepine derivative etizolam: A case report
title_sort excipient lung disease in a patient taking the benzodiazepine derivative etizolam: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818925/
https://www.ncbi.nlm.nih.gov/pubmed/35145565
http://dx.doi.org/10.1016/j.radcr.2022.01.035
work_keys_str_mv AT smithbenc excipientlungdiseaseinapatienttakingthebenzodiazepinederivativeetizolamacasereport
AT grantthomas excipientlungdiseaseinapatienttakingthebenzodiazepinederivativeetizolamacasereport
AT allenbradley excipientlungdiseaseinapatienttakingthebenzodiazepinederivativeetizolamacasereport